Autifony Tunes In To Jazz With Neurology-Focused Deal
Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.
Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.